Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2015/612567 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560796420276224 |
|---|---|
| author | Alessandro Morotti Giovanna Carrà Cristina Panuzzo Sabrina Crivellaro Riccardo Taulli Angelo Guerrasio Giuseppe Saglio |
| author_facet | Alessandro Morotti Giovanna Carrà Cristina Panuzzo Sabrina Crivellaro Riccardo Taulli Angelo Guerrasio Giuseppe Saglio |
| author_sort | Alessandro Morotti |
| collection | DOAJ |
| description | BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However, BCR-ABL TKIs do not allow completely eradicating both CML and ALL. Furthermore, ALL therapy is associated with much worse responses to TKIs than those observed in CML. The identification of additional pathways that mediate BCR-ABL leukemogenesis is indeed mandatory to achieve synthetic lethality together with TKI. Here, we review the role of BCR-ABL/protein kinase CK2 interaction in BCR-ABL leukemias, with potentially relevant implications for therapy. |
| format | Article |
| id | doaj-art-2f0e0c12d4bc4753bf96afd54d1a805b |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-2f0e0c12d4bc4753bf96afd54d1a805b2025-02-03T01:26:39ZengWileyAdvances in Hematology1687-91041687-91122015-01-01201510.1155/2015/612567612567Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive LeukemiasAlessandro Morotti0Giovanna Carrà1Cristina Panuzzo2Sabrina Crivellaro3Riccardo Taulli4Angelo Guerrasio5Giuseppe Saglio6Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyDepartment of Oncology, University of Turin, 10043 Orbassano, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyBCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However, BCR-ABL TKIs do not allow completely eradicating both CML and ALL. Furthermore, ALL therapy is associated with much worse responses to TKIs than those observed in CML. The identification of additional pathways that mediate BCR-ABL leukemogenesis is indeed mandatory to achieve synthetic lethality together with TKI. Here, we review the role of BCR-ABL/protein kinase CK2 interaction in BCR-ABL leukemias, with potentially relevant implications for therapy.http://dx.doi.org/10.1155/2015/612567 |
| spellingShingle | Alessandro Morotti Giovanna Carrà Cristina Panuzzo Sabrina Crivellaro Riccardo Taulli Angelo Guerrasio Giuseppe Saglio Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias Advances in Hematology |
| title | Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias |
| title_full | Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias |
| title_fullStr | Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias |
| title_full_unstemmed | Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias |
| title_short | Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias |
| title_sort | protein kinase ck2 a targetable bcr abl partner in philadelphia positive leukemias |
| url | http://dx.doi.org/10.1155/2015/612567 |
| work_keys_str_mv | AT alessandromorotti proteinkinaseck2atargetablebcrablpartnerinphiladelphiapositiveleukemias AT giovannacarra proteinkinaseck2atargetablebcrablpartnerinphiladelphiapositiveleukemias AT cristinapanuzzo proteinkinaseck2atargetablebcrablpartnerinphiladelphiapositiveleukemias AT sabrinacrivellaro proteinkinaseck2atargetablebcrablpartnerinphiladelphiapositiveleukemias AT riccardotaulli proteinkinaseck2atargetablebcrablpartnerinphiladelphiapositiveleukemias AT angeloguerrasio proteinkinaseck2atargetablebcrablpartnerinphiladelphiapositiveleukemias AT giuseppesaglio proteinkinaseck2atargetablebcrablpartnerinphiladelphiapositiveleukemias |